Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

References

• BogardusCTataranniPAReduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima IndiansDiabetes200251Suppl 1S262S26411815490
   PubMed Web of Science ®Google Scholar
• KingABArmstrongDUBasal bolus dosing: a clinical experienceCurr Diabetes Rev2005121522018220597
   PubMedGoogle Scholar
• GerichJENovel insulins: expanding options in diabetes managementAm J Med200211330831612361817
   PubMed Web of Science ®Google Scholar
• Levemir^® (insulin detemir [rDNA origin] injection) [prescribing information]Princeton, NJNovo Nordisk Inc2010
   Google Scholar
• SaltielARKahnCRInsulin signalling and the regulation of glucose and lipid metabolismNature200141479980611742412
   PubMed Web of Science ®Google Scholar
• KahnSEMontgomeryBHowellWImportance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitusJ Clin Endocrinol Metab2001865824582911739446
   PubMed Web of Science ®Google Scholar
• GuillausseauPJMeasTVirallyMLaloi-MichelinMMedeauVKevorkianJPAbnormalities in insulin secretion in type 2 diabetes mellitusDiabetes Metab200834Suppl 2S43S4818640585
   PubMed Web of Science ®Google Scholar
• BurcelinRKnaufCCaniPDPancreatic alpha-cell dysfunction in diabetesDiabetes Metabolism200834Suppl 2S49S5518640586
   PubMed Web of Science ®Google Scholar
• CampbellRKWhiteJRJrInsulin therapy in type 2 diabetesJ Am Pharm Assoc (Wash)20024260261112150359
   PubMedGoogle Scholar
• EliassonBEeg-OlofssonKCederholmJNilssonPMGudbjornsdottirSAntihyperglycaemic treatment of type 2 diabetes: results from a national diabetes registerDiabetes Metab20073326927617499541
   PubMed Web of Science ®Google Scholar
• OwensDRInsulin preparations with prolonged effectDiabetes Technol Ther201113Suppl 1S5S1421668337
   PubMed Web of Science ®Google Scholar
• SchmidHNew options in insulin therapyJ Pediatria (Rio J)200783Suppl 5S146S155
   Web of Science ®Google Scholar
• BeckerRHAFrickADBurgerFPotgieterJHScholtzHInsulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsExp Clin Endocrinol Diabetes200511343544316151977
   PubMed Web of Science ®Google Scholar
• OsterbergOErichsenLIngwersenSHPlumAPoulsenHEViciniPPharmacokinetic and pharmacodynamic properties of insulin aspart and human insulinJ Pharmacokinet Pharmacodyn20033022123514571692
   PubMed Web of Science ®Google Scholar
• LevyPInsulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetesMed Gen Med2007912
   PubMedGoogle Scholar
• Novolin^® R [prescribing information]Princeton, NJNovo Nordisk Inc5142010
   Google Scholar
• Novolin^® N [prescribing information]Princeton, NJNovo Nordisk Inc5142010
   Google Scholar
• WalshJARobertsRBaileyTVarmaCBUsing Insulin: Everything You Need for Success With InsulinSan Diego, CATorrey Pines Press2003
   Google Scholar
• Humalog^® (insulin lispro [rDNA origin] injection) [prescribing information]Indianapolis, INEli Lilly and Company5182011
   Google Scholar
• NovoLog^® (insulin aspart [rDNA origin] injection) [prescribing information]Princeton, NJNovo Nordisk Inc72011
   Google Scholar
• Apidra^® (insulin glulisine) [prescribing information]Bridgewater, NJSanofi-Aventis2009
   Google Scholar
• HelmsKLKelleyKWInsulin glulisine: an evaluation of its pharmacodynamic properties and clinical applicationAnn Pharmacother20094365866819336657
   PubMed Web of Science ®Google Scholar
• Lantus^® (insulin glargine [rDNA origin] injection) [prescribing information]Bridgewater, NJSanofi-Aventis322007
   Google Scholar
• PlankJBodenlenzMSinnerFA double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemirDiabetes Care2005281107111215855574
   PubMed Web of Science ®Google Scholar
• RaccahDBretzelRGOwensDRiddleMWhen basal insulin therapy in type 2 diabetes mellitus is not enough – what next?Diabetes Metab Res Rev20072325726417315242
   PubMed Web of Science ®Google Scholar
• GarberAJClausonPPedersenCBKolendorfKLower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trialsJ Am Geriatr Soc2007551735174017979896
   PubMed Web of Science ®Google Scholar
• RiddleMCRosenstockJGerichJThe Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080308614578243
   PubMed Web of Science ®Google Scholar
• HermansenKFontainePKukoljaKKPeterkovaVLethGGallMAInsulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetesDiabetologia20044762262915298338
   PubMed Web of Science ®Google Scholar
• HompeschMOcheltreeSMWondmagegnehuETPharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetesCurr Med Res Opin2009252679268719761358
   PubMed Web of Science ®Google Scholar
• KingABOnce-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover studyDiabetes Obes Metab200911697119120433
   PubMed Web of Science ®Google Scholar
• PschererSDietrichESDippelFWNeilsonARComparison of one- year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in GermanyInt J Clin Pharmacol Ther20104812913720137765
   PubMed Web of Science ®Google Scholar
• BarnettAHHow well do rapid-acting insulins work in obese individuals?Diabetes Obes Metab2006838839516776745
   PubMed Web of Science ®Google Scholar
• RoachPNew insulin analogues and routes of delivery: pharmacodynamic and clinical considerationsClin Pharmacokinet20084759561018698880
   PubMed Web of Science ®Google Scholar
• BeckerRHFrickADClinical pharmacokinetics and pharmacodynamics of insulin glulisineClin Pharmacokinet20084772018076215
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract20091554055919858063
   PubMed Web of Science ®Google Scholar
• LindholmAJacobsenLVClinical pharmacokinetics and pharmacodynamics of insulin aspartClin Pharmacokinet20014064165911605714
   PubMed Web of Science ®Google Scholar
• WutteAPlankJBodenlenzMProportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitusExp Clin Endocrinol Diabetes200711546146717647145
   PubMed Web of Science ®Google Scholar
• WangZHedringtonMSGogitidzeJNDose response effects of insulin glargine in type 2 diabetesDiabetes Care2010331555156020357371
   PubMed Web of Science ®Google Scholar
• GinHHanaire-BroutinHReproducibility and variability in the action of injected insulinDiabetes Metab20053171315803107
   PubMed Web of Science ®Google Scholar
• EMEAScientific discussion of insulin detemir2004 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000528/WC500036658.pdfAccessed November 16, 2011
   Google Scholar
• Injection site selection Available at: http://www.bd.com/us/diabetes/page.aspx?cat=7001&id=7261Accessed November 10, 2011
   Google Scholar
• MudaliarSRLindbergFAJoyceMInsulin aspart (B28 aspinsulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjectsDiabetes Care1999221501150610480516
   PubMed Web of Science ®Google Scholar
• ter BraakEWWoodworthJRBianchiRInjection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulinDiabetes Care199619143714408941480
   PubMed Web of Science ®Google Scholar
• CorsonelloAPedoneCIncalziRAAge-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactionsCurr Med Chem20101757158420015034
   PubMed Web of Science ®Google Scholar
• KronesRSchutteCHeiseTThe rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetesDiabetes Obes Metab200911414419120432
   PubMed Web of Science ®Google Scholar
• HompeschMTroupinBHeiseTTime-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groupsDiabetes Obes Metab2006856857316918592
   PubMed Web of Science ®Google Scholar
• RaveKNosekLHeinemannLFrickABeckerRTime-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteersDiabetes Metab20032943043114526272
   PubMed Web of Science ®Google Scholar
• KakuKMatsudaMUraeAIrieSPharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteersDiabetes Res Clin Pract20004911912610963823
   PubMed Web of Science ®Google Scholar
• BaysHEChapmanRHGrandySThe relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysInt J Clin Pract20076173774717493087
   PubMed Web of Science ®Google Scholar
• CrawfordAGCoteCCoutoJPrevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE centricity electronic medical record databasePopul Health Manag20101315116120521902
   PubMed Web of Science ®Google Scholar
• Fernandez-VeledoSNieto-VazquezIVila-BedmarRGarcia- GuerraLAlonso-ChamorroMLorenzoMMolecular mechanisms involved in obesity-associated insulin resistance: therapeutical approachArch Physiol Biochem200911522723919673658
   PubMedGoogle Scholar
• HolmesGGalitzLHuPLynessWPharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairmentBr J Clin Pharmacol20056046947616236036
   PubMed Web of Science ®Google Scholar
• CraigKJDonovanKMunneryMOwensDRWilliamsJDPhillipsAOIdentification and management of diabetic nephropathy in the diabetes clinicDiabetes Care2003261806181112766114
   PubMed Web of Science ®Google Scholar
• RaveKHeiseTPfutznerAHeinemannLSawickiPTImpact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patientsDiabetes Care20012488689011347749
   PubMed Web of Science ®Google Scholar
• ShrishrimalKHartPMichotaFManaging diabetes in hemodialysis patients: observations and recommendationsCleve Clin J Med20097664965519884294
   PubMed Web of Science ®Google Scholar
• HomePDPaciniGHepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agentsDiabetes Obes Metab20081069971817825080
   PubMed Web of Science ®Google Scholar
• GrayRSCowanPSteelJMJohnstoneFDClarkeBFDuncanLJInsulin action and pharmacokinetics in insulin treated diabetics during the third trimester of pregnancyDiabetes Metab19841273278
   Google Scholar
• KliegerCPollexEKazminAKorenGHypoglycemics: pharmacokinetic considerations during pregnancyTher Drug Monit20093153354119730277
   PubMed Web of Science ®Google Scholar
• GuerciBSauvanetJPSubcutaneous insulin: pharmacokinetic variability and glycemic variabilityDiabetes Metab2005314S74S2416389894
   PubMed Web of Science ®Google Scholar
• PeterRLuzioSDDunseathGEffects of exercise on the absorption of insulin glargine in patients with type 1 diabetesDiabetes Care20052856056515735188
   PubMed Web of Science ®Google Scholar
• Rabasa-LhoretRBourqueJDucrosFChiassonJLGuidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro)Diabetes Care20012462563011315820
   PubMed Web of Science ®Google Scholar
• EDIC Research GroupEpidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohortDiabetes Care1999229911110333910
   PubMed Web of Science ®Google Scholar